Creatine for the Aging Brain: 8,317 Papers Screened, Zero RCTs Found
You've probably seen the claim: creatine isn't just for gym bros, it's the next brain-health supplement. A new scoping review in Ageing Research Reviews checked what the science actually backs up. After screening more than eight thousand records, the authors found no randomized controlled trials of creatine for cognition in older adults with dementia. What they did find is a thin, messy body of evidence with one intriguing wrinkle: possible differences between males and females.
The Headline Number That Should Give You Pause
Whitford and colleagues searched PubMed, Embase, Scopus and the Cochrane Central Register of Controlled Trials with no date restrictions (English-language reports only). They followed Joanna Briggs Institute scoping-review methods and PRISMA-ScR reporting guidelines.
The search surfaced 8,317 records. Only six studies, reported across seven publications, met the criteria:
- 1 in vitro (cell-based) study
- 4 animal studies
- 1 human pilot trial, published as two papers
The authors found no relevant randomized controlled trials, the standard design for showing that a supplement works. The review itself calls the evidence "limited, heterogeneous, and predominantly preclinical."
Why Researchers Care About Creatine and the Brain
The interest isn't random. Dementia is a growing global health problem, and disease-modifying treatments remain limited. Impaired brain energy metabolism, neuroinflammation and synaptic dysfunction are shared features across dementia subtypes, and they might respond to metabolic intervention.
Creatine fits that theory. It's part of the phosphocreatine/ATP buffering system, which helps cells maintain energy supply, and it has proposed neuroprotective properties. The idea is that a brain struggling to fuel itself might benefit from a bigger energy buffer.
What the Lab and Animal Data Show
Most of the evidence is preclinical, and it leans positive but not uniformly. Across the cell and animal studies, creatine showed predominantly neuroprotective effects, attributed to bioenergetic support and modulation of neuroinflammation.
Not everything pointed the same way. One rodent study reported worsening spatial memory with supplementation. The studies also varied in design, population and intervention, which makes it hard to draw clean conclusions.
The Sex-Difference Twist
The most provocative finding came from one rodent study: female animals showed cognitive benefit, while males showed a trend toward harm.
This is one study, in animals, and a "trend" is not a confirmed effect. Still, the human pilot offered a loose parallel, with sex-divergent bioenergetic responses. That is a pattern to watch, not a conclusion. It's why the authors call for sex-stratified trials that test whether sex changes how people respond.
The One Human Study: Small and Uncontrolled
The only human data came from a pilot trial of 20 participants. According to the review details, these were people with Alzheimer's disease who took 20 g/day of creatine monohydrate for 8 weeks in an open-label design, meaning no blinding and no placebo comparison.
Results:
- Brain total creatine rose 11%.
- That rise was associated with improved fluid cognition, meaning reasoning and processing flexibility.
Those numbers are encouraging, but the design can't separate a real effect from placebo response, practice effects or expectations. The authors say the data don't support causal inference. What they do show is biological plausibility and feasibility: oral creatine can apparently raise brain creatine in this population, and people can take it.
Practical Takeaways
This section goes beyond what the review proves, so treat it as context rather than a prescription.
Dose. The standard dose used for muscle is 3–5 g/day. The human pilot used 20 g/day, far higher. Higher doses may be needed for brain uptake, but that is not established. The review specifically flags "limited understanding of optimal dosing for brain penetrance." Nobody can currently say what dose, if any, helps cognition.
Timing and duration. The only human data covered 8 weeks. There is no evidence here on the best time of day, long-term use, or whether any benefit lasts.
Who it might be relevant for. The research question concerns older adults and people with dementia. The pilot involved a very small group with Alzheimer's. There is no evidence in this review for healthy adults preventing cognitive decline.
- Anyone expecting proven cognitive benefits. They aren't proven.
- Men, as a cautious note only: one rodent study hinted at possible harm in males. That is far too preliminary to guide human decisions, but it is a reason to wait for better data.
- People with kidney problems or on multiple medications should consult a physician before taking any high-dose supplement. This is general caution rather than a finding of the review.
- Anyone considering 20 g/day should not do so without medical guidance, especially if they have dementia. Supplements are not a substitute for standard care.
Limitations to Keep in Mind
- It's a scoping review, which maps the evidence rather than judging effect sizes or pooling results.
- Only English-language reports were included.
- The six included studies differed widely in design, dose and model.
- The sole human trial had 20 participants and no control group, as described.
- The sex-specific signals come from a single rodent study and a small human sample.
The Bottom Line
Creatine for the aging brain is a plausible idea with a thin evidence base. The mechanism makes sense, animal data are mostly supportive, and one small human pilot showed brain creatine can rise and cognition may improve. But nothing here shows it prevents or treats dementia. The authors' call is clear: adequately powered, sex-stratified randomized controlled trials in adults with dementia. Until those exist, creatine for the brain remains a promising hypothesis rather than a proven strategy.
